From CMS yesterday:
On January 27, 2026, CMS announced the selection of the below list of 15 drugs payable under Medicare Part B and/or covered under Medicare Part D for the third cycle of negotiations (initial price applicability year 2028), based on total expenditures for drugs payable under Part B and/or covered under Part D and other criteria as required by the law.
The drugs selected include:
- Trulicity (dulaglutide) – Type 2 diabetes; Type 2 diabetes with cardiovascular disease or multiple cardiovascular risk factors
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) – Human immunodeficiency virus type 1 (HIV‑1) infection
- Orencia (abatacept) – Rheumatoid arthritis; Psoriatic arthritis
- Cosentyx (secukinumab) – Plaque psoriasis; Psoriatic arthritis
- Erleada (apalutamide) – Prostate cancer
- Kisqali (ribociclib) – Breast cancer
- Entyvio (vedolizumab) – Crohn’s disease; Ulcerative colitis
- Verzenio (abemaciclib) – Breast cancer
- Botox; Botox Cosmetic (onabotulinumtoxinA) – Chronic migraine; Overactive bladder; Spasticity; Other movement disorders (Medicare-covered indications)
- Lenvima (lenvatinib) – Thyroid cancer; Endometrial cancer; Liver cancer; Kidney cancer
- Xolair (omalizumab) – Asthma; Chronic spontaneous urticaria
- Rexulti (brexpiprazole) – Major depressive disorder; Schizophrenia; Agitation associated with dementia due to Alzheimer’s disease
- Xeljanz; Xeljanz XR (tofacitinib) – Rheumatoid arthritis; Psoriatic arthritis; Ulcerative colitis
- Anoro Ellipta (umeclidinium/vilanterol) – Chronic obstructive pulmonary disease (COPD)
- Cimzia (certolizumab pegol) – Crohn’s disease; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
The full CMS Fact Sheet is here.